Category

UF Startup

TearClear Announces Initiation of TC-002 Latanoprost Ophthalmic Solution Phase 3 Trial

TearClear has announced the TC-002 phase 3 trial has been successfully initiated. TearClear’s phase 3 trial (CLEAR Study) is a prospective, double-masked, randomized, multicenter, active-controlled, parallel-group, 3-month study assessing the safety and ocular hypotensive efficacy of TC-002 ophthalmic solution (TearClear Preservative-Free Latanoprost Ophthalmic Solution 0.005%) compared to marketed Latanoprost ophthalmic solution 0.005%.

Sharks: From Mortal Foes to Medical Inspiration

UF researcher Anthony Brennan's discovery that the pattern of sharkskin prevents bacteria from adhering has led to the development of company Sharklet's Foley catheter and wound dressing.

AGTC-501 Gene Therapy Offers Vision Gains for X-Linked RP

AGTC-501 (Applied Genetic Technologies Corporation), a novel gene therapy in development for the potential treatment of X-linked retinitis pigmentosa (RP), showed an acceptable safety profile and visual function improvements when administered in the study’s higher dose groups, according to Robert A. Sisk, MD, FACS, from the Cincinnati Eye Institute in Ohio.